Q-omics provides the consensus-scored TTC28 profile across patient tissues and cancer cell-line models. TTC28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC28 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TTC28 RNA expression shows 20,825 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where TTC28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC28 survival associations across molecular data types. TTC28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC28 RNA expression–survival associations across cancer types. High TTC28 expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, HNSC, LUAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC28 RNA expression.
This table summarizes TTC28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC28 shows lower tumor expression in COAD, LUAD, THCA, LUSC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher TTC28 RNA expression in tumor versus normal tissue (log2 FC = +0.971, t-test p < 0.001).
This table shows molecular features associated with TTC28 in patient tissues and cancer cell lines. In patient samples, TTC28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and OVARY.
